Management of Neurologic Diseases

  • Authors: David M. Simpson, MD; Jessica Robinson-Papp, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 4/1/16 (What's New)

Summary

  • Optimal management of patients with CD4+ cell counts < 200 cells/mm3 and negative serum toxoplasmosis antibodies is unclear
    • Cerebral toxoplasmosis without detectable serum antibodies is uncommon[Sadler 1998]
    • Some clinicians may choose to treat such patients empirically for toxoplasmosis, given the risks of brain biopsy

Action required

Keywords: Cancer, IRIS, Neurologic Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.